Company: DNLI
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001714899-25-000170
Chunk: 185

Company: Denali Therapeutics Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 185
---
,873 7 (7)— — — Stock-based compensation— — 53,196 — — 53,196 Net loss— — — — (200,828)(200,828)Other comprehensive loss— — — (3,302)— (3,302)Balance at June 30, 2024143,123,582 $1,757 $2,704,992 $(2,659)$(1,317,039)$1,387,051 Balance at March 31, 2024142,512,856 $1,751 $2,673,033 $(1,296)$(1,218,013)$1,455,475 Issuances under equity incentive plans527,308 5 6,750 — — 6,755 Vesting of restricted stock units83,418 1 (1)— — — Stock-based compensation— — 25,210 — — 25,210 Net loss— — — — (99,026)(99,026)Other comprehensive loss— — — (1,363)— (1,363)Balance at June 30, 2024143,123,582 $1,757 $2,704,992 $(2,659)$(1,317,039)$1,387,051 

See accompanying notes to unaudited condensed consolidated financial statements.

5

Denali Therapeutics Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

Six Months EndedJune 30,20252024Operating activitiesNet loss$(257,089)$(200,828)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization5,370 4,104 Stock–based compensation expense50,547 52,940 Net accretion of discounts on marketable securities(6,585)(20,574)Non-cash adjustment to operating lease expense(2,161)(1,976)Right-of-use asset amortization for finance lease1,798 — Non-cash gain from divestiture of small molecule programs— (14,537)Changes in operating assets and liabilities:Prepaid expenses and other current assets(3,650)(20,336)Other non-current assets3,022